Geography of clinical cancer research publications from 1995 to 1999

Francisco Grossi, O. Belvedere, R. Rosso

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

In this paper, we study the geography of publications in clinical cancer research from 1995 to 1999. A Medline search was performed to retrieve papers in clinical oncology reporting phase I, II and III studies published between 1995 and 1999. Only studies reporting antiblastic chemotherapy have been considered, either alone or in combination with other treatments. For each country, the total number of papers, the total Impact Factor (IF), and the mean IF were determined. Similar calculations were performed to compare the European Union versus North America. 3142 papers were identified. The United States ranks first by number of papers (37.7% share), followed by Italy (9.8%), the United Kingdom (8.5%) and Japan (6.9%). Investigators at European institutions published a higher number of papers compared with their North American colleagues (1362 versus 1288). Still the mean IF of North American papers is higher than the papers with a European address (3.54 versus 3.14). The majority of phase I studies were performed in North America, while most of phase III studies were performed in Europe. These results provide information on the geography of clinical cancer research worldwide, which may reflect the human and economic resources involved in this field.

Original languageEnglish
Pages (from-to)106-111
Number of pages6
JournalEuropean Journal of Cancer
Volume39
Issue number1
DOIs
Publication statusPublished - Jan 2003

Fingerprint

Geography
North America
Publications
Medical Oncology
European Union
Research
Italy
Neoplasms
Japan
Economics
Research Personnel
Drug Therapy
Therapeutics
United Kingdom

Keywords

  • Bibliometric analysis
  • Clinical cancer research
  • Clinical trials
  • Countries
  • Impact Factor
  • Journals
  • Medline

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Geography of clinical cancer research publications from 1995 to 1999. / Grossi, Francisco; Belvedere, O.; Rosso, R.

In: European Journal of Cancer, Vol. 39, No. 1, 01.2003, p. 106-111.

Research output: Contribution to journalArticle

Grossi, Francisco ; Belvedere, O. ; Rosso, R. / Geography of clinical cancer research publications from 1995 to 1999. In: European Journal of Cancer. 2003 ; Vol. 39, No. 1. pp. 106-111.
@article{2b079d3741b34b1784de8af4bad39f9a,
title = "Geography of clinical cancer research publications from 1995 to 1999",
abstract = "In this paper, we study the geography of publications in clinical cancer research from 1995 to 1999. A Medline search was performed to retrieve papers in clinical oncology reporting phase I, II and III studies published between 1995 and 1999. Only studies reporting antiblastic chemotherapy have been considered, either alone or in combination with other treatments. For each country, the total number of papers, the total Impact Factor (IF), and the mean IF were determined. Similar calculations were performed to compare the European Union versus North America. 3142 papers were identified. The United States ranks first by number of papers (37.7{\%} share), followed by Italy (9.8{\%}), the United Kingdom (8.5{\%}) and Japan (6.9{\%}). Investigators at European institutions published a higher number of papers compared with their North American colleagues (1362 versus 1288). Still the mean IF of North American papers is higher than the papers with a European address (3.54 versus 3.14). The majority of phase I studies were performed in North America, while most of phase III studies were performed in Europe. These results provide information on the geography of clinical cancer research worldwide, which may reflect the human and economic resources involved in this field.",
keywords = "Bibliometric analysis, Clinical cancer research, Clinical trials, Countries, Impact Factor, Journals, Medline",
author = "Francisco Grossi and O. Belvedere and R. Rosso",
year = "2003",
month = "1",
doi = "10.1016/S0959-8049(02)00239-3",
language = "English",
volume = "39",
pages = "106--111",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "1",

}

TY - JOUR

T1 - Geography of clinical cancer research publications from 1995 to 1999

AU - Grossi, Francisco

AU - Belvedere, O.

AU - Rosso, R.

PY - 2003/1

Y1 - 2003/1

N2 - In this paper, we study the geography of publications in clinical cancer research from 1995 to 1999. A Medline search was performed to retrieve papers in clinical oncology reporting phase I, II and III studies published between 1995 and 1999. Only studies reporting antiblastic chemotherapy have been considered, either alone or in combination with other treatments. For each country, the total number of papers, the total Impact Factor (IF), and the mean IF were determined. Similar calculations were performed to compare the European Union versus North America. 3142 papers were identified. The United States ranks first by number of papers (37.7% share), followed by Italy (9.8%), the United Kingdom (8.5%) and Japan (6.9%). Investigators at European institutions published a higher number of papers compared with their North American colleagues (1362 versus 1288). Still the mean IF of North American papers is higher than the papers with a European address (3.54 versus 3.14). The majority of phase I studies were performed in North America, while most of phase III studies were performed in Europe. These results provide information on the geography of clinical cancer research worldwide, which may reflect the human and economic resources involved in this field.

AB - In this paper, we study the geography of publications in clinical cancer research from 1995 to 1999. A Medline search was performed to retrieve papers in clinical oncology reporting phase I, II and III studies published between 1995 and 1999. Only studies reporting antiblastic chemotherapy have been considered, either alone or in combination with other treatments. For each country, the total number of papers, the total Impact Factor (IF), and the mean IF were determined. Similar calculations were performed to compare the European Union versus North America. 3142 papers were identified. The United States ranks first by number of papers (37.7% share), followed by Italy (9.8%), the United Kingdom (8.5%) and Japan (6.9%). Investigators at European institutions published a higher number of papers compared with their North American colleagues (1362 versus 1288). Still the mean IF of North American papers is higher than the papers with a European address (3.54 versus 3.14). The majority of phase I studies were performed in North America, while most of phase III studies were performed in Europe. These results provide information on the geography of clinical cancer research worldwide, which may reflect the human and economic resources involved in this field.

KW - Bibliometric analysis

KW - Clinical cancer research

KW - Clinical trials

KW - Countries

KW - Impact Factor

KW - Journals

KW - Medline

UR - http://www.scopus.com/inward/record.url?scp=0037216228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037216228&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(02)00239-3

DO - 10.1016/S0959-8049(02)00239-3

M3 - Article

C2 - 12504666

AN - SCOPUS:0037216228

VL - 39

SP - 106

EP - 111

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 1

ER -